Source: Rritual Superfoods Inc.
  • Rritual has increased the size of its C$3,000,000 bought deal offering
  • The underwriter has agreed to purchase 8,000,000 units for aggregate gross proceeds of C$4,000,000
  • The underwriters have been offered an over-allotment option to purchase up to an additional 1,200,000 units for total proceeds of up to $4,600,000
  • The offering is expected to close on or about September 8, 2021
  • Rritual Superfoods is a premium brand in the emerging functional mushroom & adaptogenic superfood market
  • Rritual Superfoods Inc. (RSF) is down 9.26 per cent, trading at $0.46 per share at 4 pm ET

Rritual Superfoods (RSF) is pleased to announce that, due to strong demand, it has increased the size of its previously announced C$3,000,000 bought deal offering.

The underwriter has agreed to purchase 8,000,000 units at a price of C$0.50 per unit for aggregate gross proceeds of C$4,000,000.

The company has agreed to grant the underwriters an over-allotment option to purchase up to an additional 1,200,000 units. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the offering will be $4,600,000.

The offering is expected to close on or about September 8, 2021.

Rritual Superfoods is the first award-winning, premium brand in the emerging functional mushroom & adaptogenic superfood market.

Rritual Superfoods Inc. (RSF) is down 9.26 per cent, trading at $0.46 per share at 4 pm ET.

More From The Market Online

“Paw Patrol” owners see a 52-week share price high

Spin Master (TSX:TOY) reported 8.9 per cent revenue growth to US$436.4 million and returned to profitability.

Uber Eats expands grocery delivery network with new U.S. regional retail partners

Uber (NYSE:UBER) Eats added Busch’s Fresh Food Market, Hays, and Lowe’s Market to its grocery delivery marketplace across the U.S.

Cybersecurity stocks worth watching as digital risks continue to evolve

Cybersecurity threats continue to evolve, while recent disruptions highlighted the importance of resilient digital infrastructure.

A small-cap contender looking to challenge the weight-loss drug giants

Structure Therapeutics (NASDAQ:GPCR) is developing an oral weight-loss pill that could offer an alternative to popular injectable treatments.